While this study population was specific, the magnitude of weight loss aligns with and extends the Phase 2 findings, suggesting that the 24% range is reproducible across populations at the highest dose
The sample size for TRIUMPH4 is designed to provide at least 90% power to demonstrate the superiority of retatrutide 9 and 12 mg over placebo on each of the coprimary endpoints: percent change in body weight and percent change in WOMAC pain subscale score (with similar assumptions as above)
Whether you are evaluating Ozempic, exploring retatrutide, or comparing every option in between, SeekPeptides members access the detailed analysis and personalized guidance that makes confident decisions possible
This triple-hormone receptor activation is thought to enhance the medications efficacy in promoting weight loss by targeting multiple pathways involved in energy balance and appetite regulation
Have medical reasons surgery is not appropriate right now
10.1210/endo.138.10.5270 Endocrinology 39 LennoxR.FlattP